{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Unknown+Primary+Origin",
    "query": {
      "condition": "Carcinoma of Unknown Primary Origin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 59,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Unknown+Primary+Origin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T04:53:41.657Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003548",
      "title": "Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "aminocamptothecin colloidal dispersion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "1998-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-28",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003548"
    },
    {
      "nct_id": "NCT02721732",
      "title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Carcinoma of Unknown Primary",
        "Metastatic Adrenal Gland Pheochromocytoma",
        "Metastatic Kidney Medullary Carcinoma",
        "Metastatic Malignant Germ Cell Tumor",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Paraganglioma",
        "Metastatic Penile Carcinoma",
        "Metastatic Skin Squamous Cell Carcinoma",
        "Small Cell Carcinoma",
        "Stage III Adrenal Cortex Carcinoma AJCC v7",
        "Stage IV Adrenal Cortex Carcinoma AJCC v7",
        "Stage IV Penile Cancer AJCC v7",
        "Stage IV Renal Cell Cancer AJCC v7",
        "Unresectable Adrenal Gland Pheochromocytoma",
        "Unresectable Paraganglioma",
        "Unresectable Skin Squamous Cell Carcinoma",
        "Unresectable Solid Neoplasm",
        "Vascular Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2016-08-15",
      "completion_date": "2028-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02721732"
    },
    {
      "nct_id": "NCT01366144",
      "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Carcinoma",
        "Carcinoma of Unknown Primary",
        "Endometrial Carcinoma",
        "Esophageal Carcinoma",
        "Liver Failure",
        "Lung Carcinoma",
        "Malignant Head and Neck Neoplasm",
        "Malignant Testicular Neoplasm",
        "Melanoma",
        "Metastatic Malignant Solid Neoplasm",
        "Ovarian Carcinoma",
        "Renal Failure",
        "Unresectable Malignant Neoplasm",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2011-06-20",
      "completion_date": "2027-03-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01366144"
    },
    {
      "nct_id": "NCT00360360",
      "title": "Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasm, Unknown Primary"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2006-07",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 9,
      "location_summary": "Jacksonville, Florida • Gainesville, Georgia • Evansville, Indiana + 6 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Bowling Green",
          "state": "Kentucky"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360360"
    },
    {
      "nct_id": "NCT02567422",
      "title": "Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Carcinoma of Unknown Primary",
        "Head and Neck Squamous Cell Carcinoma",
        "Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2017-04-17",
      "completion_date": "2027-05-14",
      "has_results": true,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 19,
      "location_summary": "Duarte, California • Sacramento, California • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02567422"
    },
    {
      "nct_id": "NCT01624220",
      "title": "A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Tumor"
      ],
      "interventions": [
        {
          "name": "Spinal SBRT (Standard Dose)",
          "type": "RADIATION"
        },
        {
          "name": "Spinal SBRT (Higher Dose)",
          "type": "RADIATION"
        },
        {
          "name": "Gold Seed Implantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2012-08-03",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624220"
    },
    {
      "nct_id": "NCT04754321",
      "title": "Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Carcinoma of Unknown Primary",
        "Locally Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Pharyngeal Squamous Cell Carcinoma",
        "Resectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Intraoperative Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Salvage Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2022-05-12",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04754321"
    },
    {
      "nct_id": "NCT05075980",
      "title": "Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Carcinoma",
        "Head and Neck Carcinoma of Unknown Primary",
        "Hypopharyngeal Carcinoma",
        "Laryngeal Carcinoma",
        "Metastatic Malignant Neoplasm in the Lymph Nodes",
        "Nasal Cavity Carcinoma",
        "Oral Cavity Carcinoma",
        "Oropharyngeal Carcinoma",
        "Paranasal Sinus Carcinoma",
        "Salivary Gland Carcinoma",
        "Cutaneous Squamous Cell Carcinoma of the Head and Neck",
        "Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Proton Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2022-02-16",
      "completion_date": "2031-03-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Albert Lea",
          "state": "Minnesota"
        },
        {
          "city": "Mankato",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05075980"
    },
    {
      "nct_id": "NCT00900302",
      "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 98,
      "start_date": "2005-04",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900302"
    },
    {
      "nct_id": "NCT00499733",
      "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cryoablation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 19,
      "start_date": "2007-06",
      "completion_date": "2013-01-09",
      "has_results": false,
      "last_update_posted_date": "2019-01-18",
      "last_synced_at": "2026-09-29T04:53:41.657Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499733"
    }
  ]
}